RRAS

Across TCGA pan-cancer cohorts, RRAS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RRAS data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RRAS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RRAS expression acts as an unfavorable survival marker.

CCRCC, UCEC, and PDAC are the cancer types where RRAS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.475	0.818	.001	42	view →
UCEC	DFS	Median	All	0.774	0.942	.006	22	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
LUAD	DFS	Median	All	0.833	0.966	.033	8	view →
HNSC	DFS	Median	All	0.299	0.782	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RRAS–CCRCC (DFS)

Open the CCRCC breakdown →